This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets in Acute Bacterial Cystitis.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2006 by Min-Sheng General Hospital.
Recruitment status was:  Not yet recruiting
Acrobio Healthcare Inc.
Information provided by:
Min-Sheng General Hospital Identifier:
First received: March 19, 2006
Last updated: NA
Last verified: March 2006
History: No changes posted

In conventional treatment for non-complicated bacterial cystitis, 3-day oral antibiotics could achieve good cure rate. However, severe lower urinary tract symptoms were most bothersome and only could be partially relieved by NSAID, detrusor muscle relaxants, minor tranquilizer or pyridium. Some medication associated side effects were complained while receiving adjuvant medication treatment, including gastro-intestinal discomfort, dry mouth, blurred vision, lethargy, or allergic reactions. The irritative bladder symptoms from bladder inflammation had great impact on the quality of life and well tolerable adjuvant therapy would have clinical benefit to reduce the discomfort from the bladder.

In the past years, cranberry juice or its extract has been proven to have protective effect on urothelium to prevent further bacterial ascending infection. The commercial cranberry extract tablets have good tolerability and showed good effect on symptoms reliving and infection protection on several clinical observation. In acute bladder infection, we could expect the bioactive components in cranberry could reduce the virulence of pathogens and assist to eradicate pathogens and to stable the urothelium. In literature review, only little works focusing on the symptoms relief in acute cystitis patients. To clarify the clinical benefit on lower urinary symptoms relieving, we attempt to conduct a randomized double-blind placebo-controlled trial to evaluate the effect of a compound cranberry extract tablet as an adjunctive modality in treating acute uncomplicated bacterial cystitis in otherwise healthy female patients.

Condition Intervention Phase
Pyuria Urinary Tract Infections Drug: compound cranberry extract tablet Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets (UmayC) in Acute Bacterial Cystitis.

Further study details as provided by Min-Sheng General Hospital:

Primary Outcome Measures:
  • Time to symptoms relief

Secondary Outcome Measures:
  • Pyuria eradication rate

Estimated Enrollment: 60
Study Start Date: April 2006
  Show Detailed Description


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • female patient with non-complicated acute bacterial cystitis

Exclusion Criteria:

  • recent (less than one month) urinary tract infection
  • partially treated acute cystitis
  • anatomical or function disease of the lower urinary tract
  • patients received radical pelvic surgery
  • associated bladder stone disease
  • upper urinary tract anomaly or urolithiasis
  • systemic infection with body temperature higher than 38°C
  • known allergic reaction to cranberry or vitamin C
  • pregnant or prepare to be pregnant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00305071

Contact: Po-Chien Huang, MD 886-3-3179599 ext 8223
Contact: Hung-Ju Yang, MD 886-3-3179599 ext 8225

Min-Sheng General Hospital Not yet recruiting
Taoyuan City, Taiwan, 320
Contact: Po-Chien Huang, MD    886-3-3179599 ext 8223   
Sponsors and Collaborators
Min-Sheng General Hospital
Acrobio Healthcare Inc.
Principal Investigator: Po-Chien Huang, MD Division of Urology, department of Surgery, Min-Sheng General Hospital, Taoyuan, Taiwan
  More Information Identifier: NCT00305071     History of Changes
Other Study ID Numbers: ICMJE IRB NO:950113-1
Study First Received: March 19, 2006
Last Updated: March 19, 2006

Keywords provided by Min-Sheng General Hospital:
urinary tract infections
Vaccinium macrocarpon

Additional relevant MeSH terms:
Urinary Tract Infections
Urologic Diseases
Urinary Bladder Diseases processed this record on August 17, 2017